These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8552395)

  • 1. Identification of domains required for transcriptional activation and protein dimerization in the human papillomavirus type-16 E7 protein.
    Zwerschke W; Joswig S; Jansen-Dürr P
    Oncogene; 1996 Jan; 12(1):213-20. PubMed ID: 8552395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relative ability of human papillomavirus type 6 and human papillomavirus type 16 E7 proteins to transactivate E2F-responsive elements is promoter- and cell-dependent.
    Armstrong DJ; Roman A
    Virology; 1997 Dec; 239(1):238-46. PubMed ID: 9426463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of the HPV E7 proteins with the pCAF acetyltransferase.
    Avvakumov N; Torchia J; Mymryk JS
    Oncogene; 2003 Jun; 22(25):3833-41. PubMed ID: 12813456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of the human papillomavirus type 16 E7 oncoprotein and the adeno-associated virus Rep78 major regulatory protein in vitro and in yeast and the potential for downstream effects.
    Hermonat PL; Santin AD; Zhan D
    J Hum Virol; 2000; 3(3):113-24. PubMed ID: 10881991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional studies of E7 proteins from different HPV types.
    Ciccolini F; Di Pasquale G; Carlotti F; Crawford L; Tommasino M
    Oncogene; 1994 Sep; 9(9):2633-8. PubMed ID: 8058327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CXXC Zn binding motifs of the human papillomavirus type 16 E7 oncoprotein are not required for its in vitro transforming activity in rodent cells.
    Braspenning J; Marchini A; Albarani V; Levy L; Ciccolini F; Cremonesi C; Ralston R; Gissmann L; Tommasino M
    Oncogene; 1998 Feb; 16(8):1085-9. PubMed ID: 9519882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mutational analysis of the amino terminal domain of the human papillomavirus type 16 E7 oncoprotein.
    Brokaw JL; Yee CL; Münger K
    Virology; 1994 Dec; 205(2):603-7. PubMed ID: 7975265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HPV-16 E7 oncoprotein binds Skip and suppresses its transcriptional activity.
    Prathapam T; Kühne C; Banks L
    Oncogene; 2001 Nov; 20(52):7677-85. PubMed ID: 11753645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of E7/Rb associations.
    Caldeira S; Dong W; Tommasino M
    Methods Mol Med; 2005; 119():363-79. PubMed ID: 16350411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV-18 E7 conjugates to c-Myc and mediates its transcriptional activity.
    Wang YW; Chang HS; Lin CH; Yu WC
    Int J Biochem Cell Biol; 2007; 39(2):402-12. PubMed ID: 17070091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus type 45 E7 is a transforming protein inducing retinoblastoma protein degradation and anchorage-independent cell cycle progression.
    Morandell D; Rostek U; Bouvard V; Campo-Fernández B; Fiedler M; Jansen-Dürr P; Zwerschke W
    Virology; 2008 Sep; 379(1):20-9. PubMed ID: 18649911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the FHL2 transcriptional coactivator as a new functional target of the E7 oncoprotein of human papillomavirus type 16.
    Campo-Fernández B; Morandell D; Santer FR; Zwerschke W; Jansen-Dürr P
    J Virol; 2007 Jan; 81(2):1027-32. PubMed ID: 17093190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
    Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
    Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of human papillomavirus type 16 E6 and E7 oncogenes on the activity of the transforming growth factor-beta2 (TGF-beta2) promoter.
    Murvai M; Borbély AA; Kónya J; Gergely L; Veress G
    Arch Virol; 2004 Dec; 149(12):2379-92. PubMed ID: 15290353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repression of p53 transcriptional activity by the HPV E7 proteins.
    Massimi P; Banks L
    Virology; 1997 Jan; 227(1):255-9. PubMed ID: 9007083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of S phase and apoptosis by the human papillomavirus type 16 E7 protein are separable events in immortalized rodent fibroblasts.
    Alunni-Fabbroni M; Littlewood T; Deleu L; Caldeira S; Giarrè M; Dell' Orco M; Tommasino M
    Oncogene; 2000 May; 19(19):2277-85. PubMed ID: 10822378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus-16 E7 protein inhibits the DNA interaction of the TATA binding transcription factor.
    Maldonado E; Cabrejos ME; Banks L; Allende JE
    J Cell Biochem; 2002; 85(4):663-9. PubMed ID: 11968006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational analysis of transcriptional activation by the bovine papillomavirus type 1 E6.
    Chen JJ; Hong Y; Androphy EJ
    Virology; 1997 Sep; 236(1):30-6. PubMed ID: 9299614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus E7 proteins stimulate proliferation independently of their ability to associate with retinoblastoma protein.
    Caldeira S; de Villiers EM; Tommasino M
    Oncogene; 2000 Feb; 19(6):821-6. PubMed ID: 10698500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells.
    Richon VM; Russo P; Venta-Perez G; Cordon-Cardo C; Rifkind RA; Marks PA
    Cancer Res; 1997 Jul; 57(13):2789-98. PubMed ID: 9205091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.